These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Lipid effects of switching from prescription EPA+DHA (omega-3-acid ethyl esters) to prescription EPA only (icosapent ethyl) in dyslipidemic patients. Crandell JR; Tartaglia C; Tartaglia J Postgrad Med; 2016 Nov; 128(8):859-864. PubMed ID: 27684412 [TBL] [Abstract][Full Text] [Related]
4. Update on marine omega-3 fatty acids: management of dyslipidemia and current omega-3 treatment options. Weintraub H Atherosclerosis; 2013 Oct; 230(2):381-9. PubMed ID: 24075771 [TBL] [Abstract][Full Text] [Related]
5. Prescription Omega-3 Fatty Acid Products and Dietary Supplements Are Not Interchangeable. Hilleman D; Smer A Manag Care; 2016 Jan; 25(1):46-52. PubMed ID: 26882630 [TBL] [Abstract][Full Text] [Related]
6. The clinical relevance of omega-3 fatty acids in the management of hypertriglyceridemia. Backes J; Anzalone D; Hilleman D; Catini J Lipids Health Dis; 2016 Jul; 15(1):118. PubMed ID: 27444154 [TBL] [Abstract][Full Text] [Related]
7. Cardiovascular disease and omega-3s: Prescription products and fish oil dietary supplements are not the same. Gutstein AS; Copple T J Am Assoc Nurse Pract; 2017 Dec; 29(12):791-801. PubMed ID: 29280361 [TBL] [Abstract][Full Text] [Related]
11. Omega-3 fatty acids and cardiovascular disease: new developments and applications. Harris WS; Dayspring TD; Moran TJ Postgrad Med; 2013 Nov; 125(6):100-13. PubMed ID: 24200766 [TBL] [Abstract][Full Text] [Related]
12. Effects of eicosapentaenoic acid and docosahexaenoic acid on low-density lipoprotein cholesterol and other lipids: a review. Jacobson TA; Glickstein SB; Rowe JD; Soni PN J Clin Lipidol; 2012; 6(1):5-18. PubMed ID: 22264569 [TBL] [Abstract][Full Text] [Related]
13. Comparing the Impact of Prescription Omega-3 Fatty Acid Products on Low-Density Lipoprotein Cholesterol. Sharp RP; Gales BJ; Sirajuddin R Am J Cardiovasc Drugs; 2018 Apr; 18(2):83-92. PubMed ID: 29080985 [TBL] [Abstract][Full Text] [Related]
14. Role of prescription omega-3 fatty acids in the treatment of hypertriglyceridemia. McKenney JM; Sica D Pharmacotherapy; 2007 May; 27(5):715-28. PubMed ID: 17461707 [TBL] [Abstract][Full Text] [Related]
15. Effects of switching from omega-3-acid ethyl esters to icosapent ethyl in a statin-treated patient with elevated triglycerides. Kedia AW; Lynch E Postgrad Med; 2015; 127(8):869-73. PubMed ID: 26453247 [TBL] [Abstract][Full Text] [Related]
16. Bioequivalence Demonstration for Ω-3 Acid Ethyl Ester Formulations: Rationale for Modification of Current Guidance. Maki KC; Johns C; Harris WS; Puder M; Freedman SD; Thorsteinsson T; Daak A; Rabinowicz AL; Sancilio FD Clin Ther; 2017 Mar; 39(3):652-658. PubMed ID: 28189365 [TBL] [Abstract][Full Text] [Related]
18. Overview of omega-3 Fatty Acid therapies. Bradberry JC; Hilleman DE P T; 2013 Nov; 38(11):681-91. PubMed ID: 24391388 [TBL] [Abstract][Full Text] [Related]
19. Using omega-3 fatty acids in the practice of clinical lipidology. Brown WV; Bays H; Harris W; Miller M J Clin Lipidol; 2011; 5(6):424-33. PubMed ID: 22108145 [No Abstract] [Full Text] [Related]
20. Improving lipids with prescription icosapent ethyl after previous use of fish oil dietary supplements. Reddy KJ; Chowdhury S Future Cardiol; 2016 May; 12(3):261-8. PubMed ID: 27070379 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]